WO2013109202A3 - Pharmaceutical compounds comprising cefetamet - Google Patents

Pharmaceutical compounds comprising cefetamet Download PDF

Info

Publication number
WO2013109202A3
WO2013109202A3 PCT/TR2013/000014 TR2013000014W WO2013109202A3 WO 2013109202 A3 WO2013109202 A3 WO 2013109202A3 TR 2013000014 W TR2013000014 W TR 2013000014W WO 2013109202 A3 WO2013109202 A3 WO 2013109202A3
Authority
WO
WIPO (PCT)
Prior art keywords
cefetamet
pharmaceutical compounds
treatment
infectious diseases
negative bacteria
Prior art date
Application number
PCT/TR2013/000014
Other languages
French (fr)
Other versions
WO2013109202A2 (en
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2013109202A2 publication Critical patent/WO2013109202A2/en
Publication of WO2013109202A3 publication Critical patent/WO2013109202A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

The present invention relates to pharmaceutical tablet formulations comprising cefetamet to be used in the treatment of infectious diseases caused by gram positive and gram negative bacteria.
PCT/TR2013/000014 2012-01-18 2013-01-16 Pharmaceutical compounds comprising cefetamet WO2013109202A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2012/00596 2012-01-18
TR201200596 2012-01-18

Publications (2)

Publication Number Publication Date
WO2013109202A2 WO2013109202A2 (en) 2013-07-25
WO2013109202A3 true WO2013109202A3 (en) 2014-03-20

Family

ID=47913527

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/TR2013/000014 WO2013109202A2 (en) 2012-01-18 2013-01-16 Pharmaceutical compounds comprising cefetamet
PCT/TR2013/000017 WO2013109205A1 (en) 2012-01-18 2013-01-16 Pharmaceutical tablet formulations comprising cefetamet

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/TR2013/000017 WO2013109205A1 (en) 2012-01-18 2013-01-16 Pharmaceutical tablet formulations comprising cefetamet

Country Status (1)

Country Link
WO (2) WO2013109202A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106420641A (en) * 2015-05-15 2017-02-22 烟台市华文欣欣医药科技有限公司 Method for preparing cefetamet pivoxil hydrochloride tablet composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004066910A2 (en) * 2003-01-31 2004-08-12 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
WO2006037763A1 (en) * 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
WO2011139255A2 (en) * 2010-05-04 2011-11-10 Mahmut Bilgic Pharmaceutical compositions comprising cefetamet

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2345153A1 (en) 1976-03-25 1977-10-21 Roussel Uclaf NEW ALCOYLOXIMES DERIVED FROM 7-AMINO THIAZOLYL ACETAMIDO CEPHALOSPORANIC ACID, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICINAL PRODUCTS
AU2003260803A1 (en) * 2002-08-30 2004-03-19 Orchid Chemicals And Pharmaceuticals Ltd. Sustained release pharmaceutical composition
WO2006016689A1 (en) * 2004-08-10 2006-02-16 Ono Pharmaceutical Co., Ltd. Preventive and/or remedy for lower urinary tract diseases containing ep4 agonist

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004066910A2 (en) * 2003-01-31 2004-08-12 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
WO2006037763A1 (en) * 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
WO2011139255A2 (en) * 2010-05-04 2011-11-10 Mahmut Bilgic Pharmaceutical compositions comprising cefetamet

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M P DUCHARME ET AL: "Bioavailability of syrup and tablet formulations of cefetamet pivoxil.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 37, no. 12, 1 December 1993 (1993-12-01), pages 2706 - 2709, XP055060355, ISSN: 0066-4804, DOI: 10.1128/AAC.37.12.2706 *

Also Published As

Publication number Publication date
WO2013109205A1 (en) 2013-07-25
WO2013109202A2 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
IL287381A (en) Pharmaceutical preparations of human rpe cells and uses thereof
IL231536A (en) Indazole-3-carboxamides , pharmaceutical compositions comprising them and their use in the treatment of diseases
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
IL236221A (en) Thienopyridone derivatives and pharmaceutical compositions comprising them for the treatment of diseases
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
WO2013170068A3 (en) Nuclear transport modulators and uses thereof
MX370853B (en) Formulations containing amorphous dapagliflozin.
MX366899B (en) New compounds.
IL238800B (en) Immunomodulator compounds and medicaments comprising them for use in the treatment of allergic diseases and other inflammatory conditions, infectious diseases, and cancer
HK1206623A1 (en) Pharmaceutical compositions and treatment of mastitis
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
SG11201504447XA (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
GB2498276B (en) Medicinal agent and mode of prevention of HIV contamination, prevention and treatment of diseases caused by HIV and HIV-associated diseases including AIDS.
PL2892556T3 (en) Compositions and methods relating to the treatment of diseases
PL2903608T3 (en) Pharmaceutical composition comprising propionic acid for use in the treatment of viral infections
EP2785335B8 (en) Methods and pharmaceutical compositions for the treatment of darier disease
MX355719B (en) Pharmaceutical composition in the form of an oral suspension including a flavonoid fraction and xanthan gum.
HK1219063A1 (en) Pharmaceutical compositions containing hyaluronic acid for use in the treatment of black disk disease
MX2014006201A (en) Imatinib solid dosage forms reconstituted just before use.
MX2015008171A (en) Formulation comprising amorphous agomelatine.
WO2013109202A3 (en) Pharmaceutical compounds comprising cefetamet
WO2014096300A3 (en) Antibacterial compounds
WO2014013090A3 (en) Formulation comprising amorphous fingolimod
WO2013115736A3 (en) Bilayer tablet formulations of flurbiprofen and glucosamin
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13738784

Country of ref document: EP

Kind code of ref document: A2